Current studies into retatrutide peptide reveal promising outlook for addressing excess body and non-insulin dependent disease. The compound, a dual activator of GLP-1 and GIP receptor, appears to present greater weight loss and blood sugar regulation compared existing therapies. Additional research efforts are necessary to completely evaluate its